RecruitingNCT03981003

Serum Neurofilament-light Chain and GFAP Levels in Patients From the OFSEP Cohort at Different Landmarks of Multiple Sclerosis

Serum Neurofilament-light Chain and Glial Fibrillary Acidic Proten (GFAP) Levels in Patients From the OFSEP Cohort at Different Landmarks of Multiple Sclerosis

Sponsor

Centre Hospitalier Universitaire de Nīmes

Enrollment

1,150 participants

Start Date

May 22, 2019

Study Type

OBSERVATIONAL

Conditions

Multiple Sclerosis

Summary

The investigators hypothesize that serum neurofilament-light chain (NfL) levels can provide information about the level of activity and progression of Multiple Sclerosis at different stages and landmarks of the disease. In addition, Glial Fibrillary Acidic Protein (GFAP) has also been identified as another serum biomarker of disability in MS.

Eligibility

Min Age: 15 Years

Plain Language Summary

Simplified for easier understanding

This study measures two proteins in the blood — neurofilament light chain (NfL) and GFAP — that may serve as biological markers of disease activity and nerve damage in multiple sclerosis (MS). The goal is to understand whether these blood tests can track how MS changes over time. **You may be eligible if...** - You are 15 or older - You have been diagnosed with MS according to current diagnostic criteria - You are enrolled in the French OFSEP-HD patient registry - Your disability score is between 0 and 7.0 on the standard MS disability scale **You may NOT be eligible if...** - You are under 15 - You are not enrolled in the OFSEP registry - You do not have health insurance coverage Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTBlood sample

2 x 4 ml tubes blood to screen for serum Neurofilament Light Chain and GFAP levels

Locations(28)

CHU d'Amiens

Amiens, France

CHU de Besancon

Besançon, France

CHU de Bordeaux

Bordeaux, France

CHU de Caen

Caen, France

CHU de Clermont Ferrand

Clermont-Ferrand, France

Hopital Henri Mondor

Créteil, France

CHU de Dijon

Dijon, France

CHU de Grenoble

Grenoble, France

CHU de Lille

Lille, France

CHU de Limoges

Limoges, France

CHU de Lyon

Lyon, France

Hopital Timone

Marseille, France

CHU de Montpellier

Montpellier, France

CHU de Nancy

Nancy, France

CHU de Nice

Nice, France

CHU de Nimes

Nîmes, France

Fondation Rothschild

Paris, France

Hopital Pitie Salpetriere

Paris, France

Hopital Saint Antoine

Paris, France

CH de Poissy

Poissy, France

CHU de Potiers

Potiers, France

CHU de Rennes

Rennes, France

CHU de Rouen

Rouen, France

CHU de Saint Etienne

Saint-Etienne, France

CHU de Strasbourg

Strasbourg, France

CHU de Toulouse

Toulouse, France

CHU de Tours

Tours, France

CHU de Martinique

Fort-de-France, Martinique

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03981003

Related Trials

Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)

NCT000012481 location

Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques

NCT027842101 location

Immunoglobulin Deficiency a Treatable Cause of Fatigue in Patients With Multiple Sclerosis (MS)?

NCT053577811 location

Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy

NCT058494671 location

Blood Flow Restriction for Upper Limb Rehabilitation in People With Multiple Sclerosis. A Randomized Controlled Trial (BFRT-EM)

NCT067952301 location